|
Mediate 10%20% risk of febrile neutropenia ; or low risk 10% ; but who have other known risk factors, including age 65 years, poor nutritional status, poor performance status, combination therapies, extensive prior therapies, hepatic or renal dysfunction, or uncontrolled comorbidities should also be considered for primary prophylaxis.7 Several of the studies highlighted in this issue validate these recommendations. The abstracts presented by Maxwell et al page 46 ; and Doyle et al page 34 ; confirm the value of pretreatment risk assessment and primary prophylaxis and provide useful tools for integration of the guidelines and development of practice-specific implementation plans. With the use of effective risk assessment, Doyle and colleagues saw a significant reduction in the number of hospitalizations for febrile neutropenia from 9.7% to 2.1%, a reduction in hospital days, and improvement in appropriate utilization of primary prophylaxis with CSF, all of which reduce costs. The significant costs associated with febrile neutropenia are effectively described in the analysis by Weycker and colleagues page 44 ; . Patient education regarding infection prevention, reportable signs and symptoms to allow prompt interventions, and the ongoing evaluation of patients at risk may also reduce the severity of chemotherapy-induced neutropenia and febrile neutropenia. Self-administration capabilities also should be assessed to ensure the patient receives the intended dose. Administration in a clinical setting may be required for safety or reimbursement. Much like the studies in chemotherapy-induced neutropenia, efficacy and safety in the use of the long-acting CSF pegfilgrastim Neulasta ; are the focus of several studies Belani et al, page 30; Biron et al, page 32; Pettengell et al, page 40; Ozer et al, page 38; Noga et al, page 36; Saven et al, page 42 ; . Each of these studies confirms the benefit of CSF therapy in reducing the incidence of grade 3 4 neutropenia, particularly in the first cycle of therapy. Similar efficacy and safety profiles for filgrastim Neupogen ; and pegfilgrastim are also described. Unlike the ESAs, which can be safely administered on the same day of therapy, it is recommended that CSF agents be given 24 hours after chemotherapy administration. For the sake of convenience, many clinical practices allow same-day administration of pegfilgrastim. In a randomized, double-blind analysis of 75 patients with nonHodgkin's lymphoma, Saven and colleagues page 42 ; found the duration of severe neutropenia in THE JOURNAL OF SUPPORTIVE ONCOLOGY.
Other annual compensation consists of contributions to the Company's pension schemes and other benefits. Includes total number of securities underlying options granted and long-term incentive plan awards made during the year. Appointed March 2003.
Aranesp is down pretty significantly, neulasta's down very significantly, neupogen is down significantly, epogen is roughly comparable, sensipar is roughly comparable.
Unbound Fractions of EM, DLZ, and VER in Plasma and Liver Tissue. The plasma protein binding of EM, DLZ, and VER was evaluated by the equilibrium dialysis method. Dialysis was performed with an apparatus made of clear acrylic resin and consisting of two 1.5-ml chambers separated by a cellulose dialysis membrane SC-101-M10H; DIACHEMA, Zurich, Switzerland ; . EM, DLZ, or VER was added to rat plasma at a concentrations of 5 and 20 g ml and applied to one chamber, and isotonic phosphate buffer pH 7.4 ; was applied to the other chamber. After incubation at 37C for 6 h, 0.1 ml of sample was collected from both chambers for assay. For determination of the liver tissue binding of EM, DLZ, and VER, liver tissues were homogenized with 0.1 M phosphate buffer pH 7.4 ; to prepare 10, 20, and 30% tissue homogenates. Tissue homogenates were dialyzed two times with 100 volumes of 0.1 M phosphate buffer pH 7.4 ; for 12 h to remove coenzymes. EM, DLZ, or VER was mixed with the tissue homogenates at concentrations of 2, 10, or 50 g ml, respectively. The mixture and isotonic phosphate buffer pH 7.4 ; were added to the dialysis chamber and incubated at 25C for 6 h. After the incubation, 0.5 ml of sample was collected from both sides for assay. The liver tissue unbound fraction fH ; was calculated according to the following equation.
Formulationand Overall Assessment This is an interestingproject, particularlyin light of the fact that in several of the Andean sub-region countriesthere are, far too often, problemsor obstacles to full freedom of the press. It is importantto have a clear understandingof the role of mass communication media in promoting and contributing to a democraticsociety, and this project aimsto addressthis. Technical Feasibilitv: The seminars, workshops, data bases and Web page creation seem feasible, interesting and important from a technical point of view. However, the creation of a specialized documentationcentre presents some limiting aspects in respectof its efficientfunctioningat the regional level. Financial Feasibility: Thoughthe contributionof the submittingagency is important, the budget presentedis rather high, In particularfor some of the figures staff, etc. ; . Conclusion: This project is very interestingin its objectives and importance to the developmentof freedom of the press and strengtheningof democracy in the Andean sub-region.The objectives are in line with the Declarationof Puebla and the Declarationand Workplan of Santiago.
We represented Memorial Sloan-Kettering Cancer Center MSKCC ; in connection with the acquisition by a private equity fund of a portion of MSKCC's U.S. royalty interest in Neupogen and Neulasta -- products launched by Amgen in 1991. The purchase of the Amgen royalties by the private equity fund was financed in part by a novel royalties securitization that was restructured to accommodate the sale of the royalties by MSKCC and nexavar.
The following discussion summarizes our significant properties as of December 31, 2005. For additional information regarding planned additions to our facilities, see "Item 1. Business -- Manufacturing and Raw Materials." Our principal executive offices, a majority of our administrative offices, and a significant portion of our R&D facilities are located in forty-five buildings in Thousand Oaks, California. Thirty-eight of the buildings located in Thousand Oaks are owned and seven are leased. Adjacent to these buildings are facilities that are under construction and additional land for future expansion. The Thousand Oaks, California, properties include manufacturing facilities licensed by various regulatory bodies to produce commercial quantities of Epoetin alfa, Aranesp darbepoetin alfa ; , Neulasta pegfilgrastim ; , and NEUPOGEN Filgrastim ; . Clinical manufacturing of certain of our product candidates is also performed in Thousand Oaks. We own six buildings in Longmont, Colorado, including a manufacturing complex that is licensed to produce commercial quantities of Epoetin alfa and Aranesp bulk drug substance. We have undeveloped land adjacent to the Longmont site to accommodate future expansion. We also own two buildings and lease seven buildings in Boulder, Colorado, housing process development research and manufacturing facilities. We also perform clinical manufacturing of Aranesp in Colorado. We own ten buildings and lease space in five buildings in the Seattle, Washington area, which house research, clinical manufacturing, and administrative facilities. In January 2004, we opened the Seattle research center. We also own additional land for future expansion in the Seattle, Washington area. We own five buildings in West Greenwich, Rhode Island, including two manufacturing facilities which produce commercial and clinical quantities of Enbrel etanercept ; , and lease a warehouse facility in Cranston, Rhode Island. As part of the Tularik acquisition, we assumed leases on eight buildings in South San Francisco, California, which house R&D and administrative facilities. In connection with the acquisition, we initiated an integration plan to consolidate certain Tularik leased facilities, and currently only occupy two of the eight buildings. Additionally, we assumed leases on land for future development in the South San Francisco, California area. Elsewhere in North America, we own a distribution center in Louisville, Kentucky, and a research facility in Cambridge, Massachusetts. We lease facilities for administrative offices in Washington, D.C.; San Diego, Sacramento, and Camarillo, California; and Canada, and lease four facilities for regional sales and marketing offices in the United States. Outside North America, we own twelve buildings in Juncos, Puerto Rico, including both bulk and formulation, fill, and finish manufacturing facilities and warehouse facilities. Our facilities in Juncos, Puerto Rico, are responsible for formulation, fill, and finish activities related to our production of Epoetin alfa, Aranesp, Neulasta, NEUPOGEN and ENBREL. In September 2005, we received FDA approval of a new bulk drug production plant in Puerto Rico which is used for the production of Neulasta and NEUPOGEN. We are also in process of constructing an additional bulk manufacturing plant in Juncos which will be used for the production of Epoetin alfa and Aranesp. In addition, we own additional property on the Puerto Rico Site for future expansion. We also own a European packaging and distribution center in Breda, The Netherlands. We lease facilities in nineteen European countries, Australia, New Zealand, and Japan, for administration, sales and marketing, and or development. We believe that our existing facilities, third party contract manufacturing agreements, and our anticipated additions are sufficient to meet our expected needs.
Order Neupogen
Achievement of uniform drug delivery of chemotherapeutic agents throughout solid tumors is limited by the anomalous vascularization and blood vessel permeability that have been demonstrated to exist in many solid tumors 17 ; . In addition, high interstitial pressure at the center of a tumor can prevent diffusion of drug molecules through the interstitium, once they have moved from the intravascular space into the parenchyma 8, 9 ; . These impediments to drug delivery create spatial gradients in drug concentrations such that chemotherapeutic agents at clinically acceptable doses often fail to eliminate all cancer cells in a tumor and nicardipine.
Change is the difference between baseline and the mean of the 3 end-of-period values. * Baseline values are mean SD except for triglycerides, which are medians interquartile range ; . Adjusted for baseline lipid level, age, race, sex, smoking, and BMI. Changes are medians median % change ; . To convert to mg dL, multiply cholesterol values by 38.7 and triglyceride values by 88.6.
Dr. Bausch is the Director of Protein Analysis in the department of Analytical Development at Schering-Plough Corporation in Kenilworth, New Jersey. He received his Ph.D. in 1977 from Rutgers University in New Brunswick, New Jersey in the field of Protein Chemistry. His graduate work centered on lectin-protein chemistry and lectin interaction with cell surfaces. He participated in two postdoctoral fellowships in the areas of Molecular Virology and Recombinant DNA Technology at Columbia University, NYC. He joined Schering Corporation as a Senior Scientist in 1982 and has held increasing levels of responsibility. He was promoted to his current position in 2000. Dr. Bausch has 28 employees under his supervision including 8 PhDs. Dr. Bausch's group at Schering Corporation is involved in the development of pharmaceutically active protein products and viral vectors which are derived from recombinant DNA technology. Dr. Bausch and members of his group have published several papers relating to the chemical analysis of these recombinant proteins and nicorette.
Injection could, thus, be assumed to be quite similar, the myocardial scintigrams of the two tests could be compared. The extent deficit of the baseline test was 20.8 15.1% and was 16.8 12.4% in the warmed-up test p 0.11 ; Fig. 2 ; . This difference 6.6 5.9% ; was within the inter-test variability established by analysis of baseline tests. As for the maximum deficit, there was no significant difference in this scintigraphic parameter between the baseline test 41.2 12.6% ; and the warmed-up test 39.3 12.6% ; Fig. 2 ; . Substudy B. The 10 men and 2 women of this substudy were aged 62 7 years. Seven patients had single-vessel coronary disease or single-region disease by scintigraphic imaging, and five patients had multivessel or multiregion disease. All had normal left ventricular contractility. Intertest time at both sessions was 11 3 min. Serum theophylline was 30.1 10.3 mol L. Electrocardiogram exercise parameters are summarized in Table 1. The slightly more prolonged exercise time at exercise 2 compared with exercise 1 was no longer observed with aminophylline. Heart ratesystolic blood pressure product at rest and at peak exercise was higher at exercise 2 compared with exercise 1 with and without aminophylline. Heart rate-systolic blood pressure.
On low-fat eating. These resources provide tools for the client to use as eating patterns change. Encourage gradual but progressive dietary changes. Drastic changes in eating patterns may cause frustration and discourage the client from maintaining a healthy diet over the long term. Discourage use of high-fat, low-carbohydrate, or other fad diets for weight loss. These diets may adversely affect serum cholesterol and triglyceride levels, and often are too drastic to maintain over the long term. Encourage reasonable goals for weight loss e.g., 1.0 to 1.5 lb per week and a 10% weight loss over 6 months ; . Provide information about weight loss programs and support groups such as Weight Watchers and Take Off Pounds Sensibly TOPS ; . Gradual but steady weight loss is more likely to be sustained. Recognized programs that emphasize healthy eating provide support and incentive for making lifetime dietary changes and nitazoxanide.
SKYLARK SPORT MARKETING CORPORATION CALIFORNIA CORPORATION ; 3275 CORPORATE VIEW VISTA, CA 92081 FOR: BIKING, HIKING, AND CLIMBING CLOTHING, NAMELY SHORTS, T-SHIRTS, SWEATSHIRTS, HATS, TANK TOPS, AND TROUSERS; YOGA CLOTHING, NAMELY, SHORTS, PANTS, TOPS, HATS, EYECOVERS FOR USE IN YOGA PRACTICE, SPORTS BRAS, AND HEADBANDS, IN CLASS 25 U.S. CLS. 22 AND 39 ; . FIRST USE 9-30-1992; IN COMMERCE 9-30-1992.
Issued, there's really nothing left for us to do." Except gear up for next year's events. It all adds up to more dollars going directly toward finding a cure for MS and providing muchneeded services and nizatidine.
Figure 1: Overall five year survival after primary treatment for tumour X. The graph represents the recurrence rates for all cases of tu mour X. This data however, includes a large spectrum of recurrence rates from very low early stage disease ; to very high late stage disease ; . Tumour X lesions can be divided into three types, or stages, based on the pathological examination of the resected specimen. Using the TNM classification, these can be described as stages 1, 2 and 3 as shown in the following table.
Cal Association GPhA ; , has argued that "not only has the technology to characterize proteins significantly progressed, [so has] the science and methods to characterize glycans" FDA 2006b ; . Generic drug producers claim that if the structure of the proteins can be identified and characterized, then the function will follow. Notably, Sen. Hatch also has encouraged the biotechnology industry to focus on the scientific and legal issues that must be surmounted to develop a fasttrack approach to generic biopharmaceutical drug approval. He has anticipated that some human clinical testing would be necessary to obtain this approach Kowalski 2005 ; . PRICE AND POTENTIAL SAVINGS Biopharmaceutial prices are considerably higher than those for most chemical drugs, and their cost creates concern for payers. In 2005, 2 billion was spent on prescription medications, billion of which was for biotech drugs. Overall, drug sales increased 5.4 percent from 2004 to 2005, whereas biotech sales increased by 17 percent IMS Health 2006 ; . The top three selling biopharmaceutical drugs -- filgrastim Neupogen ; , epoetin alfa Epogen ; , and interferon alfa-2b Intron A ; -- cost approximately , 000, , 000, and , 000 per patient per year, respectively Senate Judiciary Committee 2004 ; . Imiglucerase Cerezyme ; , a biopharmaceutical product approved for enzyme replacement, costs nearly 0, 000 per patient per year Anand 2005 ; . Additionally, Kaiser Permanente, the nation's largest and norco.
Globin Hgb ; response rates for both products, with darbepoetin alfa affording the advantage of a less frequent dosing interval.1-2 Although, the financial implications for the use of these products are quite significant, health care professionals must consider the impact that erythropoietic stimulating proteins ESPs ; have on quality of life QOL ; for patients receiving chemotherapy and or those with malignancy. Glaspy et al demonstrated in a study including over 2, 000 patients that epoetin alfa was effective in improving QOL and functional status in patients receiving chemotherapy, most likely as a result of increased Hgb levels.3 Demetri et al concluded that patients treated with epoetin alfa had an improvement in patient reported QOL regardless of tumor type or response.4 Additionally, in a study of over 200 anemic patients with nonmyeloid tumors receiving multicycle chemotherapy conducted by Vadhan-Raj et al, patients receiving darbepoetin alfa demonstrated an increase in patient-reported fatigue and energy scores.5 Neutropenia and its associated complication of infection continues to be a significant cause of morbidity and mortality in oncology patients receiving myelosuppressive chemotherapy.6 Risk of infection and mortality increases with the severity and duration of the neutropenic episode and with the presence of fever.7 Early intervention with broad spectrum antibiotics has been shown to improve outcomes in patients with febrile neutropenia. However, a subset of these patients requires protracted hospital stays and develop severe medical complications. Prophylactic administration of a G-CSF, filgrastim Neupogen ; or pegfilgrastim Neulasta ; , has been shown to shorten the neutropenic period, and reduce the incidence of febrile neutropenia by at least 50% in high-risk patients undergoing chemotherapy.8-11 and neupogen.
Combination of independently applied computational and experimental proteomics methods described in this paper allows confident assignment of serine hydrolase function to these proteins. The chemical proteomics technology indicates that a functional protein with an active serine is expressed in the cell. The computational proteomics technology adds details about the type of function, the structure of the functional site, and the specific residue that is likely labeled by the ABP. This combination of technologies adds significant knowledge about the family of serine hydrolases in the well-studied yeast organism and norethindrone.
Neupogen for men
VALVULAR AND CONGENTIAL HEART DISEASE a ; Uncomplicated b ; Complicated e.g. pulmonary hypertension, atrial fibrillation, history of subacute bacterial endocarditis.
Background. A variety of measures of heart rate variability have been devised to measure high-frequency 0.15-0.40 Hz ; , low-frequency 0.04-0.15 Hz ; , or ultralow-frequency 0.0033 Hz ; fluctuations in sinus cycle length. Although measures of low-frequency and ultralow-frequency heart rate variability have been shown to correlate with prognosis in several populations with ischemic heart disease, their relevance to patients with primary valvular heart disease remains to be determined. Methods and Results. Thirty-eight patients with nonischemic causes of chronic severe mitral regurgitation who were in sinus rhythm underwent 24-hour ambulatory electrocardiography as part of a prospective study of the natural history of regurgitant valvular heart disease. Patients were followed for as long as 9.2 years, and end points of mortality, progression to mitral valve surgery, and development of chronic atrial fibrillation were tabulated. Time- and frequency-domain measurements of high-frequency, low-frequency, and ultralow-frequency heart rate variability were computed and compared with resting ventricular function by radionuclide cineangiography and outcome. The standard deviation of the 5-minute mean RR intervals SDANN ; , a measure of ultralow-frequency heart rate variability, was correlated with left ventricular ejection fraction r 0.49, p 0.002 ; and right ventricular ejection fraction r 0.43, p 0.007 ; , whereas low-frequency and high-frequency heart rate variabilities were not. Heart rate, ultralow-frequency heart rate variability, and, to a lesser extent, high-frequency heart rate variability exhibited significant diurnal variation, but low-frequency heart rate variability did not. Heart rate and ultralow-frequency, low-frequency, and combined low- and high-frequency heart rate variability predicted mortality and total events. The most powerful predictor of subsequent events was SDANN. Patients with reduced SDANN were significantly more likely to develop end-point events p 0.001 ; with increased progression to mitral valve surgery p 0.001 ; as well as increased early mortality p 0.02 ; . In a multivariate proportional hazards model, SDANN retained independent predictive power p 0.001 ; . Likewise, SDANN was the only variable that was significantly associated with the subsequent development of atrial fibrillation relative risk, 3.1; p 0.03 ; . Conclusions. Ultralow-frequency heart rate variability, as measured by SDANN, correlates with right and left ventricular performance and predicts development of atrial fibrillation, mortality, and progression to valve surgery in patients with chronic severe mitral regurgitation. Circulation 1993; 88: 127-135 ; KEY WORDs * electrocardiography * valvular disease * heart rate * mitral regurgitation and norpramin.
INJECTION, EPOPROSTENOL, 0.5 MG INJECTION, EPTIFIBATIDE, 5 MG INJECTION, ERGONOVINE MALEATE, UP TO 0.2 MG INJECTION, ERTAPENEM SODIUM, 500 MG INVANZ ; INJECTION, ERYTHROMYCIN LACTOBIONATE, PER 500 MG INJECTION, ESTRADIOL VALERATE, UP TO 10 MG INJECTION, ESTRADIOL VALERATE, UP TO 20 MG INJECTION, ESTROGEN CONJUGATED, PER 25 MG INJECTION, ETHANOLAMINE OLEATE, 1OO MG Ethamolin ; INJECTION, ESTRONE, PER 1 MG INJECTION, ETIDRONATE DISODIUM, PER 300 MG INJECTION, ETANERCEPT, 25 MG INJECTION, FILGRASTIM G-CSF ; , 300 MCG NEUPOGEN ; INJECTION, FILGRASTIM G-CSF ; , 480 MCG NEUPOGEN ; INJECTION, FLUCONAZOLE, 200 MG INJECTION, FOMEPIZOLE, 15 MG Antizol ; INJECTION, FOMIVIRSEN SODIUM, INTRAOCULAR, 1.65MG INJECTION, FOSCARNET SODIUM, PER 1000 MG INJECTION, GALLIUM NITRATE, 1 MG Ganite ; INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 1 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 2 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 3 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 4 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 5 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 6 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 7 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 8 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 9 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 10 CC INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, OVER 10 CC INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, 1 GRAM INJECTION, IMMUNE GLOBULIN, 10 MG INJECTION, RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN, INTRAVENOUS, 50 MG RESPIGAM ; INJECTION, IMMUNE GLOBULIN, INTRVENOUS, LYOPHILIZED, 500 MG INJECTION, IMMUNE GLOBULIN, INTRVENOUS, NON-LYOPHILIZED, 500 MG INJECTION, GANCICLOVIR SODIUM, 500 MG INJECTION, GARAMYCIN, GENTAMICIN, UP TO 80 MG INJECTION, GATIFLOXACIN, 10 MG INJECTION, GLATIRAMER ACETATE, 20 MG COPAXONE ; INJECTION, GOLD SODIUM THIOMALATE, UP TO 50 MG INJECTION, GLUCAGON HYDROCHLORIDE, PER 1 MG INJECTION, GONADORELIN HYDROCHLORIDE, PER 100 MCG INJECTION, GRANISETRON HYDROCHLORIDE, 100 MCG KYTRIL ; INJECTION, HALOPERIDOL, UP TO 5 MG INJECTION, HALOPERIDOL DECANOATE, PER 50 MG INJECTION, HEMIN, 1 MG Panhematin ; INJECTION, HEPARIN SODIUM, HEPARIN LOCK FLUSH ; , PER 10 UNITS INJECTION, HEPARIN SODIUM, PER 1000 UNITS INJECTION, DALTEPARIN SODIUM, PER 2500 IU INJECTION, ENOXAPARIN SODIUM, 10 MG LOVENOX ; INJECTION, FONDAPARINUX SODIUM, 0.5 MG INJECTION, TINZAPARIN SODIUM, 1000 IU INNOHEP ; INJECTION, HISTAMINE, UP TO 2.75 MG INJECTION, TETANUS IMMUNE GLOBULIN, HUMAN, UP TO 250 UNITS INJECTION, HISTRELIN ACETATE, 10 MCG INJECTION, HYDROCORTISONE ACETATE, UP TO 25 MG INJECTION, HYDROCORTISONE SODIUM PHOSPHATE, UP TO 50 MG INJECTION, HYDROCORTISONE SODIUM SUCCINATE, UP TO 100 MG SOLU-CORTEF ; INJECTION, DIAZOXIDE, UP TO 300 MG INJECTION, IBUTILIDE FUMARATE, 1 MG INJECTION, INFLIXIMAB, 10 MG REMICADE ; INJECTION, IRON DEXTRAN, 50 MG INJECTION, IRON DEXTRAN 165, 50 MG InFed ; INJECTION, IRON DEXTRAN 267, 50 MG DexFerrum ; INJECTION, IRON SUCROSE, 1 MG INJECTION, IMIGLUCERASE, PER UNIT CEREZYME ; INJECTION, DROPERIDOL, UP TO 5 MG INJECTION, PROPRANOLOL HCL, UP TO 1 MG INJECTION, DROPERIDOL AND FENTANYL CITRATE, UP TO 2 ML AMPULE and nexavar.
| Neupogen hydrochloride
Neupogen oral
Nepuogen, neupohen, neup9gen, neuupogen, neupogwn, neupoten, nehpogen, neupogne, neupog3n, nneupogen, neupogsn, neuoogen, ne7pogen, meupogen, nrupogen, eupogen, neupogeh, neupkgen, nupogen, neuogen, neupogenn, neupoben, neipogen, neupogfn, neuppogen, neupoyen, neupofen, neupgoen, neuplgen, heupogen, neu0ogen, nekpogen, neupogrn.
|
|
